ZOLL® offers a unique portfolio of novel technologies designed to deliver better insights and better outcomes. On any given day, clinicians utilize these products for tens of thousands of cardiac patients around the world.
90% one-year survival in patients who experienced VT/VF1
With 20+ years of clinical evidence and real-world use across more than one million patients, the LifeVest® wearable cardioverter defibrillator (WCD) is the trusted solution to provide protection for patients at risk of sudden cardiac death.
38% relative risk reduction in 90-day readmissions2
HFMS is a non-invasive, patch-based device that uses novel radiofrequency technology for early detection of changes in pulmonary fluid levels, an increase in which is an early indicator of heart failure decompensation.
26% relative infarct size reduction and improvement of left ventricular function in LAD STEMI3-6
SSO2 Therapy is the first and only FDA-approved treatment that has been clinically proven to significantly reduce damage to cardiac muscle in heart attack patients after coronary angioplasty with stenting.3 The extent of damaged cardiac muscle is a strong predictor of future outcomes like rehospitalization and the development of heart failure.7
Address the ~80% of cardiac patients with undiagnosed sleep apnea8
Sleep apnea is associated with adverse outcomes for cardiac patients.8,9 Let WatchPAT® shoulder the burden of sleep apnea management. Highly accurate, reassuringly reliable, easy to use, and scalable to fit the needs of your practice.10,11
ZOLL is ready to assist you in meeting your care goals. The team that has protected 1M+ LifeVest patients over 20+ years now provides a suite of solutions. Connect with an expert for personalized support.
GET IN TOUCH